Further trials are needed to confirm whether targeting the ALK pathway can reverse PH; present data indicate that inhibition of the activin receptor-like kinase pathway might result in slight reversal ([S]-crizotinib, IN-1233, K02288) or even progression ([R]-crizotinib) of pulmonary hypertension. Here, ALK is linked to pulmonary arterial hypertension.